logo
  

Omeros Corp. (OMER) Is Surging On Phase 2 Study Results

Omeros Corp. (OMER) announced positive results from its Phase 2 clinical trial of OMS721, for the treatment of thrombotic microangiopathies, Tuesday morning.

Omeros has gapped open sharply higher Tuesday and is now up 9.88 at $24.45 on the highest volume in 5 1/2 months. The stock has jumped to a 3 1/2 month high and has re-crossed is 50 and 200-day moving averages.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
RELATED NEWS
Follow RTT